Evidence map›Paper›PMID 40009796›Full record

ArticleMicrobiology spectrum2025

GrcC1 mediates low-level resistance to multiple drugs in

Cuiting Fang, Han Zhang, Jing He, Xirong Tian, Sanshan Zeng, Xingli Han, Shuai Wang, Buhari Yusuf, Jinxing Hu, Nanshan Zhong and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Dual Mutations inInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Cuiting FangState Key Laboratory of Respiratory Disease, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, China.ORCID 0000-0002-8045-3098
Han ZhangState Key Laboratory of Respiratory Disease, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, China.
Jing HeState Key Laboratory of Respiratory Disease, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, China.
Xirong TianState Key Laboratory of Respiratory Disease, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, China.
Sanshan ZengState Key Laboratory of Respiratory Disease, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, China.
Xingli HanState Key Laboratory of Respiratory Disease, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, China.
Shuai WangState Key Laboratory of Respiratory Disease, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, China.
Buhari YusufState Key Laboratory of Respiratory Disease, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, China.
Jinxing HuState Key Laboratory of Respiratory Disease, Guangzhou Chest Hospital, Guangzhou, Guangdong, China.
Nanshan ZhongGuangzhou National Laboratory, Guangzhou, Guangdong, China.
Yamin GaoState Key Laboratory of Respiratory Disease, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, China.ORCID 0000-0003-4131-3444
H M Adnan HameedState Key Laboratory of Respiratory Disease, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, China.ORCID 0000-0003-1993-9547
Tianyu ZhangState Key Laboratory of Respiratory Disease, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, Guangdong, China.ORCID 0000-0001-5647-6014

Funding

Bureau of Science and Information Technology of Guangzhou Municipality | Guangzhou Municipal Science and Technology Project (Guangzhou Science and Technology Plan) 2024A04J4273MOST | National Key Research and Development Program of China (NKPs) 2021YFA1300904National Foreign Expert Project QN2022031002LPresident's International Fellowship Initiative-CAS 2023VBC0015State Key Laboratory of Respiratory Disease (SKLRD) SKLRD-Z-202301State Key Laboratory of Respiratory Disease (SKLRD) SKLRD-Z-202412,SKLRD-OP-202324State Key Laboratory of Respiratory Disease (SKLRD) SKLRD-Z-202414
6 · The paper itself

Abstract

The escalating threat of mycobacterial infectious diseases, particularly those caused by nontuberculous mycobacteria (NTM), poses a serious challenge to public health. Linezolid (LZD), an oxazolidinone antimicrobial, exhibits potent activity against

Indexed as

Anti-Bacterial AgentsBacterial ProteinsDrug Resistance, Multiple, BacterialMycobacterium abscessusMycobacterium marinumMycobacterium smegmatisCell WallHumansLinezolidMicrobial Sensitivity TestsMutationMycobacterium Infections, NontuberculousWhole Genome SequencingAnti-Bacterial AgentsBacterial ProteinsLinezoliddrug resistance mechanismGrcC1Mycobacterium abscessusMycobacterium marinumMycobacterium smegmatis

Identifiers

PMID40009796
PMCPMC11960048

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.